Clinical trials: in Brazil
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- ENLIGHTEN-10 (NCT07900633)
- Testing
- Eloralintide
- Where
- 309 sites in United States, Argentina and 19 more
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Crohn Disease
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe…
- Trial name
- ICONIC-CD (NCT07196722)
- Testing
- Icotrokinra
- Where
- 395 sites in United States, Argentina and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Janssen Research & Development, LLC
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 104 sites in United States, Brazil and 9 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Multiple Myeloma
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab…
- Trial name
- MajesTEC-7 (NCT05552222)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Where
- 270 sites in United States, Australia and 23 more
- Volunteers
- 1,590 people
- Sponsor
- Janssen Research & Development, LLC
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or…
- Trial name
- RAINFOL-03 (NCT07166094)
- Testing
- Rina-S, IC
- Where
- 178 sites in United States, Australia and 17 more
- Volunteers
- 660 people
- Sponsor
- Genmab
Non-Muscle Invasive Bladder Neoplasms
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus…
- Trial name
- MoonRISe-3 (NCT06919965)
- Testing
- TAR-210, Mitomycin C, Gemcitabine
- Where
- 115 sites in United States, Argentina and 13 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical…
- Trial name
- MACARONI-23 (NCT05923073)
- Testing
- Guselkumab
- Where
- 85 sites in United States, Australia and 15 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Lupus Erythematosus, Systemic
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks…
- Trial name
- GARDENIA-SLE (NCT07438496)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 272 sites in United States, Argentina and 31 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Crohns Disease, Colitis, Ulcerative
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile…
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Trial name
- TRILOGY (NCT06663332)
- Testing
- Guselkumab
- Where
- 53 sites in United States, Argentina and 16 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with…
- Trial name
- cAMeLot-2 (NCT06852222)
- Testing
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA)
- Where
- 270 sites in United States, Australia and 24 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination…
- Trial name
- PolyDamas (NCT05908734)
- Testing
- Cetrelimab, Amivantamab
- Where
- 44 sites in United States, Brazil and 7 more
- Volunteers
- 71 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Hemolytic Disease of the Fetus and Newborn
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neonates (baby just after birth) of pregnant participants who are at risk…
- Trial name
- GERANIUM (NCT07194070)
- Testing
- Standard of Care
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 175 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by…
- Trial name
- KLK2-PASenger (NCT07225946)
- Testing
- Pasritamig, Docetaxel, Prednisone/Prednisolone
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 800 people
- Sponsor
- Janssen Research & Development, LLC
Non-Muscle Invasive Bladder Neoplasms
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
- Trial name
- MoonRISe-1 (NCT06319820)
- Testing
- TAR-210, Gemcitabine, MMC
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 641 people
- Sponsor
- Janssen Research & Development, LLC
Oily Skin
Evaluation of Dermal Acceptability and Comedogenic and Acnegenic Potential of a Cosmetic Product
This is a single-center, single-blind clinical study designed to evaluate the dermatological safety of a cosmetic product and to demonstrate the absence of comedogenic and acnegenic potential.
- Trial name
- NCT07768800
- Testing
- Blancy Pro
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Non-small Cell Lung Cancer
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C.
- Trial name
- NCT07554339
- Testing
- Calderasib, Durvalumab
- Where
- 107 sites in United States, Argentina and 16 more
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07160608
- Testing
- Tarperprumig
- Where
- 57 sites in Argentina, Australia and 12 more
- Volunteers
- 78 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.
- Trial name
- DPT02 (NCT04482309)
- Testing
- Trastuzumab deruxtecan
- Where
- 89 sites in United States, Australia and 15 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Peripheral Arterial Disease
Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease
This study will validate the efficacy and safety of the VESTO® Vascular Stent for treating patients with iliac peripheral arterial obstructive disease in a post-market clinical trial
- Trial name
- VESTO-ILIAC (NCT06573437)
- Testing
- Vascular Stent - Vesto Endoprosthesis
- Where
- 6 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.